Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • DRL recalls 80,000...

    DRL recalls 80,000 plus bottles of Atorvastatin from US due to quality concerns

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-02-09T11:28:41+05:30  |  Updated On 17 Aug 2021 12:07 PM IST

    HYDERABAD: Dr. Reddy's Laboratories has initiated a voluntary recall of over 80,000 bottles of its drug Atorvastatin Calcium Tablets 10mg, 20mg and 40mg from the US market due to quality concerns.


    Atorvastatin is a drug that blocks the production of cholesterol and reduces its level in the blood.


    According to a notification issued by the US Food and Drug Administration (USFDA), multiple lots of Atorvastatin 10 mg, 90 count, and 500 count bottles; 20 mg, 90 count and 500 count bottles and 40 mg, 90 count bottles, are being withdrawn from the market. Dr. Reddy's officials were not immediately available for comment.


    The product is being recalled through three separate letters to the drug regulator.


    According to the USFDA, the reason for the recall was,


    "Failed Impurities/Degradations specifications; out-of-specification results observed for Total Degradation Impurities during stability."


    The product was manufactured at the drug maker's Srikakulam plant in Andhra Pradesh.


    The drug is being recalled under "not yet classified" category which, according to the FDA, means that a firm's action meets the definition of a recall, however, the FDA has not completed its assessment of the hazard posed by the recalled product(s) yet, and is considered a pending classification.


    "Once FDA completes the hazard assessment, the Enforcement Report entry will be updated with the recall classification (Class I, II or III) indicating the hazard posed by the recalled product(s)," said FDA.


    Meanwhile, Glenmark Pharmaceuticals in a separate letter also initiated a voluntary recall of 5,136 tunes of its Mometasone Furoate Cream, USP, 0.1 percent 45gm from the US market due to violations of the CGMP (current good manufacturing practice) regulations set up by the USFDA.


    Mometasone Furoate Cream is used to treat skin conditions such as eczema, psoriasis, allergies, and rash.

    AtorvastatinAtorvastatin Calcium Tabletscholesterolcurrent good manufacturing practiceDr Reddy'sDr Reddy's LaboratoriesGlenmark PharmaceuticalsMometasone Furoate Creamquality concernsrecallSrikakulam plantUSUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok